Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 691-719-4 | CAS number: 1072957-71-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
2 Year rat study NOAEL = 100 ppm (4.88 mg/kg/day). Treatment related increase in thyroid follicular cell adenoma was observed in top dose (600 ppm) males.
80 Week mouse study NOAEL = 60 ppm (7.55 mg/kg/day). No treatment-related increase in tumour incidence
Key value for chemical safety assessment
Justification for classification or non-classification
Mode of action studies are ongoing to investigate the human relevance of the thyroid tumours observed in rats. A final judgment on classification for carcinogenicity will be made once these studies are completed.
Carcinogenicity: Based on the available information the substance does not meet the criteria for classification as "carcinogen" under Regulation (EC) 1272/2008, Annex I, Part 3, 3.6.2; reason for non-classification: inconclusive.
Additional information
SYN545192 has been evaluated for carcinogenic potential in the rat and the mouse.
In a 2 year combined chronic toxicity/carcinogenicity study in Wistar rats, SYN545192 was tested at dietary inclusion levels of 0, 25, 100 and 600 ppm (males) or 400 ppm (females). Significantly lower body weight gain, food consumption and food utilisation were observed in both sexes at the top dose. ALP, ALT and AST values were consistently lower than control values at the top dose. In males at 600 ppm, liver weight (covariate analysis with body weight) was statistically significantly increased. There were no other effects on organ weight. The incidence of centrilobular hypertrophy in the liver was statistically significantly higher in top dose males and females at 52 and 104 weeks. In males at 600 ppm, the incidence of eosinophilic cell foci in the liver was statistically significantly higher after 104 weeks and a higher incidence of hepatocyte vacuolation was seen after 104 weeks. A higher incidence of pigmented hepatocytes was observed in females at 400 ppm after 52 and 104 weeks. In males at 600 ppm, there was a treatment-related increase in the incidence of thyroid follicular cell adenomas. There were no other treatment-related neoplastic findings. A NOAEL was established at 100 ppm (4.88 mg/kg/day in males and 6.66 mg/kg/day in females).
In a carcinogenicity study in the mouse, groups of 50 male and 50 female CD-1 mice were fed diets containing 0, 20, 60 or 200 ppm of SYN545192 for a period of at least 80 weeks. Statistically significantly lower group mean body weight was observed in males treated with 200 ppm during the first 7 weeks of the study. This was associated with a statistically lower group mean body weight gain compared to the control animals over the first 4 weeks of the study.There was a higher incidence of simple mucosal hyperplasia in the large intestine (colon and caecum) at 200 ppm in males and females that was considered to be treatment related. The effect was more pronounced in males based on incidence and severity. In the colon the incidences were 13/49 in males and 10/48 in females. These higher incidences attained statistical significance in both sexes when compared with controls. In the caecum the incidences were 4/50 in males and 2/48 in females. These micropathology findings provide clear evidence of systemic toxicity at 200 ppm. There was no effect on the large intestine at either 20 or 60 ppm. There were no treatment-related neoplastic findings in this study. Although there was a higher incidence of Harderian gland adenoma in the treated groups when compared with controls, this difference was considered to be incidental to treatment:
· There was no dose-response relationship such that the Harderian gland tumour incidence at the low dose was higher than the historical control range whereas the incidence in the mid-dose was within the historical range
· There was no statistical significance using pairwise tests and there was no statistically significant trend using the Peto trend test
· There were no indications of any pre-neoplastic micropathology findings in the Harderian gland
· There were no increases in the incidence of adenocarcinoma in the Harderian gland, and there was no indication of any increase in tumour incidence in the Harderian gland in the rat
· The Harderian gland is a rodent specific structure with no anatomical equivalent in humans (Aldert et al 1986 the
Harderian Gland: Its tumours and its relevance to humans. Trans Am Ophthalmol 84; 321-341).
The NOEL for the 80 week mouse study was established at 60 ppm, which is equivalent to 7.55 mg/kg/day in males and 8.67 mg/kg/day in females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.